

Epithelial-Mesenchymal-Transition-Like and TGF β Pathways Associated with Autochthonous Inflammatory Melanoma Development in Mice

Maria Wehbe^{1,2,3}, Saïdi M. Soudja^{1,2,3}, Amandine Mas^{1,2,3}, Lionel Chasson^{1,2,3}, Rodolphe Guinamard^{1,2,3}, Céline Powis de Tenbossche⁴, Grégory Verdeil^{1,2,3}, Benoît Van den Eynde⁴, Anne-Marie Schmitt-Verhulst^{1,2,3*}

1 Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille Université UM2, Marseille, France, **2** Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France, **3** Centre National de la Recherche Scientifique (CNRS), Marseille, France, **4** Ludwig Institute for Cancer Research and Cellular Genetics Unit, UCL, Brussels, Belgium

Abstract

We compared gene expression signatures of aggressive amelanotic (Amela) melanomas with those of slowly growing pigmented melanomas (Mela), identifying pathways potentially responsible for the aggressive Amela phenotype. Both tumors develop in mice upon conditional deletion in melanocytes of *Ink4a/Arf* tumor suppressor genes with concomitant expression of oncogene *H-Ras^{G12V}* and a known tumor antigen. We previously showed that only the aggressive Amela tumors were highly infiltrated by leukocytes concomitant with local and systemic inflammation. We report that Amela tumors present a pattern of de-differentiation with reduced expression of genes involved in pigmentation. This correlates with reduced and enhanced expression, respectively, of microphthalmia-associated (*Mitf*) and *Pou3f2/Brn-2* transcription factors. The reduced expression of *Mitf*-controlled melanocyte differentiation antigens also observed in some human cutaneous melanoma has important implications for immunotherapy protocols that generally target such antigens. Induced Amela tumors also express Epithelial-Mesenchymal-Transition (EMT)-like and TGF β -pathway signatures. These are correlated with constitutive *Smad3* signaling in Amela tumors and melanoma cell lines. Signatures of infiltrating leukocytes and some chemokines such as chemotactic cytokine ligand 2 (*Ccl2*) that contribute to leukocyte recruitment further characterize Amela tumors. Inhibition of the mitogen-activated protein kinase (MAPK) activation pathway in Amela tumor lines leads to reduced expression of EMT hallmark genes and inhibits both proinflammatory cytokine *Ccl2* gene expression and *Ccl2* production by the melanoma cells. These results indicate a link between EMT-like processes and alterations of immune functions, both being controlled by the MAPK pathway. They further suggest that targeting the MAPK pathway within tumor cells will impact tumor-intrinsic oncogenic properties as well as the nature of the tumor microenvironment.

Citation: Wehbe M, Soudja SM, Mas A, Chasson L, Guinamard R, et al. (2012) Epithelial-Mesenchymal-Transition-Like and TGF β Pathways Associated with Autochthonous Inflammatory Melanoma Development in Mice. PLoS ONE 7(11): e49419. doi:10.1371/journal.pone.0049419

Editor: Bart O. Williams, Van Andel Institute, United States of America

Received: June 13, 2012; **Accepted:** October 7, 2012; **Published:** November 16, 2012

Copyright: © 2012 Wehbe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by institutional funding from INSERM and CNRS, and by grants from the "Institut National du Cancer" (INCA) and the INCA PROCAN program (to AMSV), the European Communities (Integrated project "Cancerimmunotherapy" LSHC-CT-2006-518234 to AMSV and to BVdE) and the "Association pour la Recherche sur le Cancer" (to AMSV). MW and SMS were the recipients of doctoral fellowships from the "Association pour la Recherche sur le Cancer." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: verhulst@ciml.univ-mrs.fr.

Introduction

Melanoma tumors arise from neural crest-derived melanocytes, cells specialized in the synthesis of melanin pigments [1]. The transition from normal melanocytes to metastatic melanomas occurs through a multistage process [2]. The acquisition of invasive behavior in cancers of epithelial origin is due in part to a phenotypic switch called epithelial-mesenchymal-transition (EMT). In this process, epithelial cells lose contacts with neighboring cells and assume migratory characteristics. EMT, described as the developmental switch undergone by cells from a polarized epithelial to a motile mesenchymal phenotype during embryonic development, has emerged as a central process of cancer progression [3–5]. It is characterized by decreased epithelial and increased mesenchymal markers [6]. Many EMT inducers such as TGF β [7] have been identified, and molecular

mechanisms related to the highly invasive characteristics of cancer cells have been intensively investigated [3,6]. In particular, oncogenic Ras or activation of the MAPK pathway and TGF β have been shown to cooperatively regulate epithelial cell plasticity and invasiveness [5,8,9].

We have described a mouse model of inducible melanoma based on the conditional deletion of the *Ink4a/Arf* tumor suppressor genes with concomitant expression of the *H-Ras^{G12V}* oncogene and the cancer-germline gene *P1A (Trap1a)*, encoding a natural mouse tumor antigen. We previously showed that two types of cutaneous tumors expressing *P1A* develop in induced mice: pigmented melanomas (Mela) that grow slowly and amelanotic (Amela), more aggressive tumors [10]. Both types of melanomas were deleted at the *Ink4a/Arf* locus and expressed transcripts for *H-Ras^{G12V}*, albeit expression was higher in the Amela tumors [11]. The more aggressive Amela

melanomas were highly infiltrated by leukocytes concomitant with local and systemic inflammation [11]. Neither tumor infiltration by leukocytes nor systemic inflammation was observed in Mela-bearing mice.

Here we compare the gene expression signatures of both tumor types, identifying pathways potentially responsible for the aggressive Amela phenotype. We show (i) a de-differentiated phenotype with reduced expression of *Mitf*, (ii) expression of genes akin to those defining EMT and (iii) expression of genes encoding chemokines and immuno-modulating cytokines characterizing aggressive (Amela) compared to slow progressor (Mela) melanomas. EMT-like and TGF β -pathway signatures, correlated with constitutive Smad3 signaling, also characterized Amela tumor cells. Inhibition of the MAPK activation pathway in Amela tumor lines led to reduced Smad3 signaling, affected expression of EMT hallmark genes and inhibited proinflammatory cytokine *Ccl2* gene expression and production by the melanoma cells. We conclude that in this model of autochthonous inflammatory melanoma, EMT-like processes and alterations of immune functions are linked, both being controlled by the MAPK pathway.

Results

Segregation of Mela, Amela and Normal Skin Gene Expression Profiles

To characterize the molecular differences between Mela and Amela tumors, we performed gene expression microarrays on 8 whole tumor samples, as well as on a pool of healthy mouse skins (see Methods and Fig. S1). Skin from control mice was chosen for the gene expression studies because it corresponds to the environment in which the tumors develop that may have topical characteristics in terms of stromal cells and leukocytes that are also present in the tumors.

To identify more precisely the genes differentially expressed between Mela and Amela tumors, gene expression array datasets were subjected to the microarray data analysis program Significance Analysis of Microarrays (SAM) [12]. This analysis revealed 1195 genes differentially expressed between the two types of tumors (>2 fold, *p* value <0.001), 813 of which were down-regulated in Amela versus Mela tumors.

Using hierarchical clustering analysis, three distinct groups were identified based on the similarity of their expression patterns. These segregated Mela from Amela tumors and both tumors from normal skin. Examples of clusters of genes are shown (i) upregulated selectively in Amela-tumors (Fig. S1A), (ii) up- and down-regulated, respectively, in Mela- and Amela-tumors (Fig. S1B), (iii) up-regulated (Fig. S1C) or (iv) down-regulated (Fig. S1D) in both Amela and Mela tumors, as compared to normal skin.

Down-regulation of Transcripts Controlling Melanocyte Differentiation in Amela Tumors is Associated with up-regulation of *Pou3f2/Brn2* Transcripts and Increased Aggressiveness

According to microarray data, transcripts controlling pigmentation, keratinization and epidermis development were down-regulated in Amela versus Mela tumors (Fig. 1A-Table S1). These include (Fig. 1A–E) genes (*Tyrp1*, *Si*, *Mlana*) encoding melanosomal proteins (Tyrosinase related protein 1/gp75, Silver/gp100, Melan-A/Mart-1), as well as genes encoding transcription factors *Mitf*, *Pax3* and *Sox10*, known to be required for expression of the melanosomal proteins (for review [13]). This pattern of gene expression was verified by quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) in Amela versus Mela

tumors (Fig. 1B), as well as in the corresponding tumor lines (Fig. 1C). QRT-PCR data also confirmed that the gene encoding the master transcription factor for melanocyte differentiation (*Mitf*), which is highly expressed in Mela tumors, was down-regulated in Amela tumors (Fig. 1D). In man, a correlation between MITF expression in primary melanomas and survival has been described, with de-differentiated melanomas being associated with poor prognosis [14]. Interestingly, the *Pou3f2* gene encoding a transcription factor also called *Brn2* showed higher expression in Amela compared to Mela tumors (Fig. 1A, E). This is consistent with data showing *Brn2* expression up-regulation by Ras and MAPK signaling [15] and BRN2 repression of MITF expression in some human melanoma cell lines [16]. These results are in agreement with the reported correlation between the aggressiveness of human melanomas and down-regulation of expression of genes controlling melanocyte differentiation, including *MELANA*, *MC1R*, *PAX3* and *c-KIT* [17,18].

Inflammatory Gene Expression Profile in Amela Tumors

Among the genes with up-regulated expression in Amela tumors, some characterize immune response components or chemotaxis (Tables 1- Table S2). To distinguish signatures of leukocytes infiltrating selectively Amela tumors from those intrinsic to the tumor, we compared gene expression profiles of whole Amela tumors with their *in vitro* derived cell lines (see Methods). This analysis permitted us to identify the transcriptional signatures for the Amela tumor infiltrates (genes down-regulated more than twofold in the Amela tumor lines compared to the whole Amela tumors) (Table S2). Most of these genes were characterized by a myeloid lineage expression, while some pertained to lymphocytes or stromal cells (Table S2), in agreement with our previous cellular analysis. Indeed, the Amela tumor infiltrate was found to be composed mainly of myeloid cells, a majority of which expressed the CD11b and Gr-1 markers, akin to “Myeloid Derived Suppressor Cells (MDSC)”, whereas T cells composed about 10% of the hematopoietic cell infiltrate [11].

We also identified Amela tumor-intrinsic expressed genes (Table 1). Some encode factors involved in angiogenesis such as *Vegfa*, or molecules involved in signaling and controlling proliferation or invasion. Interestingly, among the genes considered as signatures for leukocytes selectively infiltrating Amela tumors (Table S2), some encode receptors (*ccr1*) for chemokines encoded by genes (*ccl2*, *ccl5*, *ccl7*) expressed in Amela tumors (Table 1).

Thus, inflammation, possibly initiated by cytokines produced by Amela tumors (see later section), may be further amplified by myeloid cells recruited by tumors [11].

Gene Set Enrichment Analysis

To identify pathways that might impart the phenotypes described for the two types of melanomas we performed gene set enrichment analyses (GSEA) using gene set 2.0 (<http://www.broadinstitute.org/gsea>). Specifically, an established collection of more than 100 cancer related, curated gene sets provided by the Molecular Signatures Database (MSigDB, www.broadinstitute.org/gsea/msigdb) as well as those collected from the literature, were used to interrogate the gene expression dataset in order to compare gene set enrichment in each type of melanoma.

We found 40 gene signatures specifically enriched in either the Amela tumors or in the Mela tumors (*p* < 0.05) (not shown). Notably, a significant number of the gene sets enriched in the Amela versus the Mela tumors were classifiers for either EMT or pathways known to induce EMT, such as TGF β pathways (Fig. 2A-Fig. S2).




Figure 1. Differential expression in Amela and Mela tumors of genes involved in pigmentation, differentiation and development of melanocytes. A. Microarray data as log2 for Amela and Mela tumors are shown in arbitrary units (a.u.). For these genes, ratio of gene expression as log2 Amela/Mela is < -1 (a) or between -1 and 0 (b) with p values < 0.05 ; for Pou3f2 (c), ratio of gene expression as log2 Amela/Mela is > 1 with p value < 0.05 . B–C. Validation of expression of four genes (from A) by QRT-PCR in Amela and Mela tumors *ex vivo* (B) and of corresponding melanoma lines cultured *in vitro* (C). D–E. Relative expression of transcripts for *Mitf* (D) and for *Brn2/Pou3f2* (E) in induced Mela and Amela tumors *ex vivo*. Amela tumors are represented by white dotted bars and Mela tumors by black dotted bars. For *ex vivo* analysis (B, D, E) values were normalized to those for skins of control mice, 6 samples of each tumor and 4 skin samples were analyzed. For *in vitro* analysis (C), 3 different cDNA preparations from two Mela and 8 Amela tumor lines were used and values were normalized to those for B16F10 cells. *** p value < 0.001 ; ** p value < 0.01 ; * p value < 0.05 (see methods).
doi:10.1371/journal.pone.0049419.g001

Table 1. Amela tumor-intrinsic expressed genes controlling angiogenesis, invasion and cytokines.

Gene symbol	Gene name	^(b) Log2 ratio Amela/Mela	^(c) Log2 ratio Amela/Line
^(a) Angiogenesis			
Vegfa	Vascular endothelial growth factor A	1.45	−1.71
Foxc2	Forkhead box C2	1.36	−0.40
Tnfaip2	Tumor necrosis factor, alpha induced protein 2	1.32	−0.91
Adamts1	a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1, motif, 1	1.12	0.07
^(a) Proliferation and invasion			
Igfbp3	Insulin-like growth factor binding protein 3	3.15	0.64
Lox	Lysyl oxidase	2.5	0.33
Tbx3	T-box 3	2.4	−0.4
Stat4	Signal transducer and activator of transcription 4	2.10	−1.62
Igfbp4	Insulin-like growth factor binding protein 4	1.70	1.64
Axl	AXL receptor tyrosine kinase	1.68	0.07
Socs3	Suppressor of cytokine signaling 3	1.31	0.08
Loxl2	Lysyl oxidase-like 2	1.2	0.17
^(a) Immune response and chemotaxis			
Ccl2	Chemokine (C-C motif) ligand 2	2.25	−2.46
Cxcl5	Chemokine (C-X-C motif) ligand 5	2.19	0.75
Il6	Interleukin 6	1.66	0.72
Ccl5	Chemokine (C-C motif) ligand 5	1.61	−1.57
Ltbp1	Latent transforming growth factor beta binding protein 1	1.86	−0.657
Pla2g7	Phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)	1.55	−0.98
Chst2	Carbohydrate sulfotransferase 2	1.40	0.98
Ccl7	Chemokine (C-C motif) ligand 7	1.38	−1.03
Cxcl10	Chemokine (C-X-C motif) ligand 10	1.23	−0.48
Uaca	Uveal autoantigen with coiled-Coil domains and ankyrin repeats	1.19	0.45
F8	Coagulation factor 8	1.07	−0.11

^(a)Genes characterizing angiogenesis, proliferation and invasion, immune response components or chemotaxis that show higher expression in Amela versus Mela primary tumors and are expressed at similar level in Amela primary tumors and Amela lines in culture.

^(b)Ratio of gene expression as Log2 primary Amela/primary Mela > 1 with p value < 0.001;

^(c)Ratio of gene expression as Log2 primary Amela/cultured Amela line < 1 or with p value n.s.).

doi:10.1371/journal.pone.0049419.t001

Aggressive Amela Tumors are Associated with a Signature Akin to EMT

In agreement with the GSEA analysis, among the genes distinguishing Amela from Mela tumors and qualifying as intrinsically tumor-expressed, we identified genes encoding proteins associated with melanoma progression, akin to those characterizing EMT (Table 2). These include transcriptional regulators Hmga2, Twist1 and Snail1, whose expression is up-regulated, and Id2, whose expression is down-regulated. Changes in adhesion molecule transcripts (down-regulation of E-cadherin/*Cdh1*, up-regulation of N-cadherin/*Cdh2* and integrin alpha 5/*Itga5* transcripts) also characterize EMT.

We next compared the mRNA level of different epithelial and mesenchymal markers on both types of tumors by QRT-PCR. As shown in Fig. 2B, the Amela tumors expressed higher levels of transcripts for mesenchymal markers (Snail1, Twist1 and Hmga2) than Mela tumors and a lower level of E-cadherin/*Cdh1* and *Id2* transcripts. Given recent reports implicating Snail1 in both inflammation and EMT-like processes in the skin [19] or in melanoma cells [20], we analyzed its expression by immunohistology on Amela tumors (Fig. S3). It should be noted that staining

with the commercially available anti-Snail1 antibody revealed mostly cytoplasmic Snail1, although Snail1's function as a repressor of transcription is dependent on its nuclear localization [21]. Snail1 shuttles between the cytoplasm and the nucleus in a regulated manner that is not fully understood. Post-translational modifications including phosphorylation on serine and threonine residues, ubiquitination and lysine oxidation affect Snail1 protein stability, subcellular localization and activity [21–24]. Thus, although Snail1 appears to be expressed in Amela tumors, further biochemical analyses would be required to analyze post-translational modifications of the protein and their influence on its localization and function.

Genes Involved in the TGFβ Pathway in Amela Lines

Since the GSEA analysis showed a significant enrichment of genes involved in TGFβ pathways, we identified the genes upregulated in the Amela tumors known to take part in the TGFβ pathways based on the literature (Table 3). In particular, transcripts encoding components of the TGFβ pathway (Ltbp1, Igfbp3) are upregulated in Amela tumors, although no active TGFβ appeared to be secreted (see next section).



A**B**

Figure 2. EMT and TGF β pathway signatures in Amela melanomas. A. Representative gene set enrichment analysis (GSEA) plots of EMT (right graph) and TGF β pathway (left graph) gene signatures. Each plot is divided into two sections. The first section (class A) shows results for gene sets that have a positive enrichment score (gene sets that show enrichment at the top of the ranked list here associated with Amela samples). The second section (class B) shows the results for gene sets that have a negative enrichment score (gene sets that show enrichment at the bottom of the ranked list here associated with Mela samples). Data provided as in Fig. S2. **B.** QRT-PCR analysis for expression of transcripts encoding mesenchymal and epithelial markers in Amela (white dotted bars) and Mela (black dotted bars) tumors. Values were normalized to those for skin from control mice. Data are represented as mean $\pm$ s.e.m of three independent experiments in which 7 samples of Amela and 7 samples of Mela tumors were analyzed. **p value < 0.01; *p value < 0.05. doi:10.1371/journal.pone.0049419.g002

TGF β acts as tumor suppressor in early cancer. In later stages of cancer, however, TGF β can promote tumors toward invasive and metastatic phenotypes [25,26]. TGF β binding to its receptor induces the formation of a heteromeric complex composed of TGF β receptor type II (T β RII) and I (T β RI). The latter transmits

the signal through phosphorylation of receptor-regulated Smads such as Smad2 and Smad3. Both of those Smads form heteromeric complexes with Smad4 and are then translocated into the nucleus, where they regulate expression of target genes both by direct DNA

Table 2. Genes up-regulated or down-regulated in Amela tumors involved in EMT.

Gene symbol	Gene name	^(b) Log2 ratio Amela/Mela	^(c) Log2 ratio Amela/Lines
^(a) Cell adhesion/ECM matrix/Cytoskeleton			
Itgbl1	Integrin beta like 1	2.18	0.20
Lamb1-1	Laminin beta 1, subunit 1	1.47	-0.76
Sdc2	Syndecan-1	1.36	0.36
Cdh2	N-cadherin	1.25	-0.33
Col4a1	Collagen, type IV, alpha 1	0.99*	0.87
Col11a1	Collagen, type XI, alpha 1	0.81*	-0.54
Itgav	Integrin alpha 5	0.62*	-0.30
Col6a1	Collagen, type VI, alpha 1	0.57*	0.96
Itga3	Integrin alpha 3	0.46*	-1.90
^(a) Proteases . Protease inhibitors			
Mmp10	Metallopeptidase 10	2.67	1.26
Pcolce	Procollagen C-endopeptidase enhancer protein	1.03	-0.93
Mmp19	Metallopeptidase 19	0.92*	0.20
Serpib9	Serine peptidase inhibitor, Clade B, member9	0.72*	0.75
^(a) PDGF/PDGF receptor pathway			
Ccl2	Chemokine CC motif ligand 2	2.23	-2.46
Pdgfc	Platelet derived growth factor, C polypeptide	1.59	-0.31
Cmkor1	Chemokine CXC motif receptor 7 (CXCR7)	1.46	-0.52
Pdgfa	Platelet derived growth factor, alpha	0.67	0.39
Pdgfd	Platelet derived growth factor, D polypeptide	0.47	0.26
^(a) Hypoxia			
Upp1	Uridine phosphorylase	1.74	-0.75
Il11	Interleukin 11	1.69	-0.97
Hif1a	hypoxia inducible factor 1, alpha subunit	0.59*	-1.46
^(a) Transcription factors			
Hmga2	high mobility group alpha 2	3.71	-1.05
Twist1	Twist homolog 1 (Drosophila)	2.07	-0.78
Foxc2	Forkhead box c2	1.36	-0.40
Snai1	Snail homolog 1 (Drosophila)/Snail1	1.16	-0.07
^(d) Down-regulated in Amela			
Cdh1	E-Cadherin	-3.62	2.28
Id2	Inhibitor of DNA binding 2	-0.83*	0.6

^(a)Genes known to be involved in EMT that show higher expression in Amela versus Mela primary tumors and are expressed at similar level in Amela primary tumors and Amela lines in culture.

^(b)Ratio of gene expression as log2 primary Amela/primary Mela > 1 with p values < 0.05;

*Ratio of gene expression as log2 primary Amela/primary Mela between 0 and 1 with p values < 0.05;

^(c)Ratio of gene expression as Log2 (primary Amela-/cultured Amela line) < 1 and/or with p value > 0.05 (ns). Log2 (primary Amela /cultured Amela line) < - 1 corresponds to higher expression in cultured Amela line than in primary Amela.

^(d)Genes known to be involved in EMT that show lower expression in primary Amela versus Mela tumors.

doi:10.1371/journal.pone.0049419.t002

binding and through interaction with other transcription factors, coactivators, and corepressors.

We used computational methods to test the hypothesis that some of the genes within the Amela up-regulated cluster are coordinately regulated by the Smad3 transcription factor. Using the Clover program, we found a significant statistical enrichment for conserved Smad binding sites in the promoters of genes highly expressed in Amela tumors as compared to background sequences. Analysis of promoter sequences identified many genes with multiple, conserved Smad binding sites (Table S3).

Evidence for Constitutive Activation of the TGFβ Pathway in Amela cell lines and tumors

To measure TGFβ bioactivity from Amela cell culture supernatants with high sensitivity we used the SBE-SEAP reporter line MFBF11 [27] (see methods). Samples that were not activated with acid did not induce reporter activity. After activation with acid, all samples were able to strongly induce reporter activity, showing that Amela tumor cells express the latent form of TGFβ (Fig. 3A).

We transduced Amela as well as B16F10 melanoma cell lines with the lentivirus-based Smad3-reporter vector expressing green fluorescent protein (SBE-GFP) [28]. Surprisingly, even in the

Table 3. Representative TGF β Related Genes expressed in Amela tumors and cultured cell lines.

TGF β related genes				
(a)Gene symbol	Gene name	(b)log ₂ ratio Amela/Mela	(c)log ₂ ratio Amela /Lines	(d)References
Igfbp3	Insulin-like growth factor binding protein 3	3.15	0.64	[1]
Cspg2	Versican	2.55	0.04	[2–4]
Itgbl1	Integrin beta-like 1	2.18	0.20	[4]
Cald1	Caldesmon 1	1.93	−0.08	[5–7]
Ltbp1	Latent transforming growth factor beta binding protein 1	1.78	−0.66	[8]
Nid1	Nidogen	1.72	0.66	[9]
Igfbp4	Insulin-like growth factor binding protein 4	1.60	1.64	[10]
Lamb1–1	Laminin B1 subunit 1	1.47	−0.76	[4,7,11–12]
Cmkor1	Chemokine CXC motif receptor 7 (RDC1, CXCR7)	1.46	−0.52	[2,6,12–14]
Fhl2	Four and a half LIM domains 2	1.43	−0.40	[2,6–7,12–13]
Lrp1	Low density lipoprotein receptor-related protein 1	1.40	0.88	[15]
Plat	Plasminogen activator, tissue	1.40	0.99	[16]
Bmp1	Bone morphogenetic protein 1	1.30	0.54	[6–7,12]
Smad3	MAD homolog 3 (Drosophila)	1.19	−0.23	[17]
Slc29a1	Solute carrier family 29 (nucleoside transporters), member 1	1.18	1.00	[5,7,12]
Cdh6	Cadherin 6	1.18	0.28	
Rdh10	Retinol dehydrogenase 10 (all-trans)	1.11	0.29	[6–7,13]
Col4a1	Collagen type IV, alpha 1	0.99*	0.87	[7,11–13]
Wnt2	Wingless-related MMTV integration site 2	0.97*	0.48	[18]
Tgfb β 2	Transforming growth factor receptor 2	0.96*	0.01	[19]
Marcks1	MARCKS-like 1	0.94*	0.88	[20]
Rhoq	Ras homolog gene family, member Q	0.90*	0.37	[20]
Ext1	Extososomes multiple 1	0.85*	0.43	[2,6–7]
Ier3	Immediate early response 3	0.84*	−0.43	[5,7,12–13]
Tgfb β 3	Transforming growth factor 3	0.82*	0.23	[19]
Pdgfa	Platelet derived growth factor, alpha	0.67*	0.39	[2,5–7,21]
Col6a1	Collagen type VI, alpha 1	0.57*	0.96	[4,7,22]
Itga3	Integrin alpha 3	0.46*	−1.90	[4,7,23]
Cd44	CD44 antigen	0.41*	−1.47	[24]
Skil	SKI-like	0.40*	0.49	[2,7,13]
Igf2r	Insulin-like growth factor 2 receptor	0.38*	0.10	
Tgfb β 3	Transforming growth factor receptor 3	0.20*	−0.23	[19]

(a) Genes known to be TGF β responsive that show higher expression in Amela versus Mela primary tumors and are expressed at similar level in Amela primary tumors and in Amela lines in culture.

(b) Ratio of gene expression as log₂ primary Amela/primary Mela > 1 with p values < 0.05;

*Ratio of gene expression as log₂ primary Amela/primary Mela between 0 and 1 with p values < 0.05;

(c) Ratio of gene expression as Log₂ (primary Amela/cultured Amela line) < 1 and/or with p value > 0.05 (ns). Log₂ (primary Amela/cultured Amela line) < -1 corresponds to higher expression in cultured Amela lines than in primary tumor.

(d) Numbered references can be found in Text S1.

doi:10.1371/journal.pone.0049419.t003

absence of TGF β , we detected GFP-fluorescent Amela tumor cells, but no fluorescent B16F10 cells (Fig. 3B), although all cell populations responded to TGF β induction. A heterogeneous constitutive GFP expression was observed in all tested Amela lines. Based on GFP expression in these cells in the presence or absence of added TGF β , Amela cells were sorted by FACS. Amela cells expressing GFP constitutively are called Amela^C and Amela cells expressing GFP after TGF β -induction are called Amela^I. QRT-PCR analysis showed higher expression of 3 selected Smad3-regulated genes in Amela^C compared to Amela^I cells (Fig. 3C).

To explain the constitutive activation of Smad3 in Amela^C cells, we wondered if this population expressed active TGF β , which was not detected when analyzing supernatants from the whole population. To test this hypothesis, supernatants of Amela^C and Amela^I cells were tested in the SBE-GFP-reporter assay. Only acid-treated supernatants from both cell types induced reporter activity, showing that the basal activation of Smad3 in Amela^C cells did not result from autocrine TGF β (Fig. 3, Fig. S4A).




Figure 3. Analysis of the TGF β pathway in melanoma lines and tumors. **A.** Supernatants from Amela cell lines incubated in serum-free DMEM were either acid treated (acid) or not (no treatment) and were tested for TGF β content using reporter line MFBF11 (see Methods). Bars represent means $\pm$ s.d. of triplicate wells in one representative experiment. Serum-free DMEM (no TGF β) was used for baseline measurement. **B.** Flow cytometry analysis of GFP expression in SBE-GFP-transduced Amela and B16F10 cell lines preincubated in serum-free DMEM without addition (red lines) or in the presence of TGF β (blue lines). Non-transduced Amela cell lines were used as control (gray filled). **C.** Comparison of the expression of 3 genes associated with EMT by Amela^C and Amela^I cell lines by QRT-PCR (see text). Results are represented as fold change in relative expression where the value for Amela^C is set to 1 for each gene. Data are represented as mean $\pm$ s.e.m. of two independent experiments in which 4 different lines of each type were tested. **D-E.** Flow cytometry analysis of GFP expression in SBE-GFP-transduced Amela^C cell lines as in (B). The effect of various

inhibitors was assessed on Amela^C cells during the incubation in serum-free DMEM without (-) or with addition (+) of TGF β . GFP expression in one Amela^C line before and after treatment with various inhibitors in the absence of TGF β is shown in (D). In (E) results show fold change of mean GFP fluorescence intensity in Amela^C without (panel at left) or with (panel at right) addition of TGF β . The value for Amela^C in the absence of TGF β is set to 1. Data are represented as mean $\pm$ s.e.m of four independent experiments. ***p value < 0.001; **p value < 0.01; *p value < 0.05.
doi:10.1371/journal.pone.0049419.g003

Involvement of Ras Signaling Pathways in Smad Activation in Amela Tumors

Smads are modular proteins with conserved Mad Homology 1 (MH1), intermediate linker and MH2 domains. T β RI phosphorylates the COOH-terminal serine residues of Smads (pSmad3C). The linker domain may be phosphorylated (pSmad3L) by Ras-dependent kinases such as extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) [29]. We investigated the role of the Ras signaling pathways in Smad3 constitutive activity in Amela^C cells (Fig. 3D). Constitutive expression of GFP in the Amela^C cells was significantly inhibited only by JNK inhibitor, SP600125 (Fig. 3D–E). It was not inhibited by either SIS3, a specific inhibitor of TGF β -induced Smad3 phosphorylation, or by SB431542, an inhibitor of T β RI kinase activity (Fig. 3D–E). In contrast, both SIS3 and SB431542 were efficient at inhibiting TGF β -induced GFP expression in Amela^C lines. This result suggests that Ras signaling may be involved in inducing Smad3 activity in Amela^C cells via activation of JNK.

EMT in Amela Tumor Cells is Controlled by MAPK Signaling Pathways

If the active Ras/MAPK pathway is responsible for activation of the transcriptional activity of Smad3 leading to expression of an EMT-like transcriptional program, it was expected that inhibition of that pathway would lead to down-regulation of the expression of genes characterizing EMT. To test this possibility, we analyzed the effects of JNK and ERK inhibitors on the expression of various genes by QRT-PCR (Fig. 4A). The JNK inhibitor (SP600125) led to downregulation of *Snail1*/*Snail1*, *Fn1*, *Cdh2* and upregulation of *Cdh1* transcripts. *Hmga2* and *Vim* transcripts were decreased in the presence of the ERK (PD 98059), but not the JNK inhibitor. These data are concordant with previous results in other tumor types for *Hmga2* [30]. When combining JNK and ERK inhibitors, however, a further inhibition of *Hmga2* transcripts was observed.

Amela Tumors Express High Levels of Phosphor-Smad3L and Phosphor-JNK in vivo

Given the enrichment in genes involved in the TGF β pathway detected in the Amela tumors, we tested whether pSmad3L could be detected by immunohistology on tumor sections (Fig. 5A). Antibody to CD45 was used to identify tumor-infiltrating leukocytes together with anti-pSmad3L antibody. In the Amela tumors a high frequency of tumor cells were labeled with anti-pSmad3L antibody, whereas most infiltrating leukocytes were not labeled. In Mela tumors, few infiltrating leukocytes were detected and most tumor cells were negative or very weakly stained with anti-pSmad3L antibodies. When analyzing expression of phosphorylated JNK (pJNK), we similarly observed strong staining in Amela tumors and very weak staining in the Mela tumors (Fig. 5B). These data show a correlation between JNK activation revealed by pJNK and Smad3 phosphorylation in its linker domain, and suggest that Smad3 is constitutively active in the Amela tumors as it is in the corresponding cell lines.

Proinflammatory Ccl2 Cytokine Production in Amela Tumor Cells is Controlled by MAPK Signaling Pathways

We further analyzed the control of production of the proinflammatory cytokine Ccl2 and confirmed by QRT-PCR data the differential expression of its transcript between Amela and Mela tumors (Fig. 6A), as well as by cultured Amela and Mela tumor cell lines (Fig. 6B). Cytokine production was readily detected in 24 h supernatants of Amela, but not of Mela, nor of B16.F10 lines (Fig. 6C). We next addressed whether production of the proinflammatory cytokine was under the control of the MAPK pathway by testing the effect of the inhibitors on Ccl2 gene expression (Fig. 6D) and cytokine production (Fig. 6E) by the Amela tumor cells. Data indicate a significant inhibition of Ccl2 transcripts and cytokine production when cells were incubated in the presence of the JNK inhibitor or the ERK and JNK inhibitors (Fig. 6).

These results suggest that oncogenic Ras expression coordinately controls expression of an EMT and a proinflammatory gene expression program via activation of the MAPK pathway.

Discussion

We sought to understand the molecular bases of tumor cell heterogeneity in the autochthonous TiRP mouse melanoma model. To do this, we compared gene expression profiles of the slowly progressing pigmented Mela and fast growing amelanotic Amela tumors. These tumors arise as a result of Cre-mediated deletion of the *Ink4a/Arf* genes in melanocytes together with expression of H-ras^{G12V} and P1A encoding a mouse tumor antigen. These events were observed in both types of tumors although higher levels of H-ras^{G12V} and P1A transcripts were detected in Amela tumors [10,11]. A threshold level of H-ras^{G12V} may be required for oncogenic H-ras to signal to any of the several downstream pathways, which it can activate. These include the MAPK pathways involving notably ERK and JNK, as well as phosphoinositide-3-kinase/Akt and NF- κ B pathways [31,32]. Combined with absence of p16/Arf tumor suppressors, the level of H-ras^{G12V} may thus control key factors determining differentiation (Brn2, Mitf), EMT (JNK, Smad3, TGF β signaling) and Ccl2 production (MAPK, JNK) during melanoma development as discussed hereafter.

Mice developing Amela melanomas presented a systemic Th2-profile of cytokines [11] associated with high expression of Vegfa by the tumors (Table 1), a situation analogous to that found in patients with metastatic melanoma [33]. *Il6* was also up-regulated selectively in the Amela melanomas (Table 1), in agreement with high level detection of Il-6 in Amela tumor supernatant and serum of Amela-bearing mice [11] and with previous reports on its induction by oncogenic Ras in different cell types [34], including melanomas in a distinct model of H-ras^{G12V}-induced melanoma in mice [35].

Other cytokine genes expressed selectively by Amela tumors include those encoding Ccl2, Ccl5, and Ccl7 (Table 1), all 3 of which can contribute to the recruitment of Ccr1-expressing myeloid leukocytes (Table S2). This pattern of cytokine gene expression is thus consistent with the identified immune cell gene expression signature in the Amela tumors (Table S2) and myeloid




Figure 4. Effect of MAPK pathway inhibitors on the expression of EMT hallmark genes in Amela tumor lines. QRT-PCR analysis for expression of 6 transcripts encoding mesenchymal and epithelial markers in Amela tumor cells in the absence (value set to 1) or presence of inhibitors, as indicated. Data are represented as mean $\pm$ s.e.m of three independent experiments in which 5 samples were analyzed. ***p value < 0.001; **p value < 0.01; *p value < 0.05.
doi:10.1371/journal.pone.0049419.g004

cell infiltrate detected in the Amela tumors [11]. The latter may in turn amplify inflammation in the tumor microenvironment [11].

Tumor expression of the proinflammatory cytokine Ccl2, also called monocyte chemoattractant protein 1 (MCP1), has been associated with macrophage migration to the tumor and promotion of tumor growth in transplanted tumor models [36] and human melanoma xenografts [37]. More recently, Ccl2 has also

been implicated in recruitment of MDSC to transplanted tumors [38] and to an autochthonous glioma [39] in mice. These data are in line with our observation of a strong myeloid infiltrate in Amela tumors [11] and a gene expression signature for Amela-infiltrating myeloid cells producing additional inflammatory cytokines (Table S2).




Figure 5. Analysis of phosphorylated Smad3 and JNK in melanoma tumors. Sections of Amela and Mela tumors were analyzed by immunohistology after staining with anti-CD45 mAb (green) and with anti-Phospho-Smad3L (pSmad3L) (A) or with anti-Phospho-JNK (pJNK) (B) (red). Sytox blue stains nuclei (white). Bars correspond to 50 μ m in the 4 quadrant-figures and to 20 μ m in the magnifications of the highlighted fields (labeled 1 and 2). In A, the brightfield image is superimposed on the “merge” image. Images are representative of 3 tumors of each type. Immunofluorescence was quantified using NIH ImageJ software for the determination of relative densities of expression of given markers within fixed section areas (fraction area). Values were, respectively (A) 1.95 ± 0.73 for Mela and 13.78 ± 1.55 for Amela tumor Phospho-Smad3L staining (unpaired t test $p < 0.0001$) and (B) 5.39 ± 1.05 for Mela and 26.36 ± 3.26 for Amela Phospho-JNK staining (unpaired t test $p < 0.0005$). doi:10.1371/journal.pone.0049419.g005

Evidence for the role of local inflammation in the promotion of melanoma progression has recently accumulated although the initiating events and the nature of the infiltrating cells may differ. For instance, ultraviolet B radiation (UVB), a major contributor to skin carcinogenesis, was shown to promote melanomagenesis in neonatal mice transgenic for hepatocyte growth factor (HGF) via recruitment of IFN γ -producing macrophages to neonatal skin by UVB-induced ligands to the chemokine receptor Ccr2 [40,41], a process which does not occur in adult mice. Interestingly, HGF has been shown to induce epithelial scattering through MAPK-mediated upregulation of Snail1 [42].

In addition to this proinflammatory circuit in Amela tumors, we observed a gene expression signature characterizing an EMT-like process, which was not expressed by Mela tumors. Therefore a signaling link may exist between inflammatory cytokine gene expression and an EMT-like gene expression profile.

Amela melanomas showed a decrease in E-cadherin/*Cdh1* transcripts compared to Mela tumors. E-cadherin expression was decreased in melanoma cell lines compared to normal human epidermal melanocytes [43]. In contrast, transcripts for N-cadherin/*Cdh2*, another member of the cadherin family, were up-regulated in Amela cells. Loss of E-cadherin and gain of N-cadherin expression is known as “cadherin switching” [44]. It can promote motility and invasion of cancer cells and is usually observed in EMT, especially in melanoma [45].

Amela cells also expressed zinc-finger transcription factor Snail1, a transcriptional repressor of E-cadherin expression [46]. Expressed in many cancers, Snail1 was reported to regulate genes involved in EMT-like processes during malignant melanoma development [47]. TGF β is a major inducer of Snail1 expression [48], associated with EMT [25,49]. Our microarray results showed a higher expression of genes associated with TGF β signaling in Amela compared to Mela tumors. Although not




Figure 6. Specific expression of Ccl2 in Amela tumors is controlled by Ras signalling pathways. (A–B) QRT-PCR analysis of Ccl2 transcript expression in induced Mela and Amela primary tumors (A) and in the corresponding cell lines *in vitro* (B). (C) Concentration of secreted Ccl2 in the supernatant of 24 h cultures of Amela and Mela cell lines as measured by ELISA. (D) Expression of Ccl2 transcript by QRT-PCR and (E) concentration of secreted protein by ELISA, in the absence (value set to 1) or presence of inhibitors in 24 h cultures, as indicated. (A–C) Amela tumors are represented by white dotted bars and Mela tumors by black dotted bars. For primary tumor analysis (A) 6 samples of each tumor were analyzed. For *in vitro* analysis (B), values were normalized to those for B16F10 cells. In (C), supernatants from 24 h cell cultures were tested and values are expressed as ng/ml. In D–E, culture conditions were as described in Methods. Experiments involved 10 Amela lines in (D) and 4 in (E). ****p value < 0.0001; ***p value < 0.001; **p value < 0.01; *p value < 0.05.

doi:10.1371/journal.pone.0049419.g006

secreting active TGF β , Amela cells appear to secrete the inactive form of TGF β , which can be activated by different factors. We observed a constitutive activity of the TGF β signaling pathway in Amela lines in the absence of exogenous TGF β , which did not result from autocrine stimulation through T β RI (Fig. 3, Fig. S4A). Rather, it may depend on JNK activity which probably resulted from the activation of the Ras pathway in the Amela tumor lines, in agreement with studies on H-Ras^{G12V} transformed epithelial lines [7,50] and patient colorectal tumors [50,51]. The higher expression of H-Ras^{G12V} in the Amela as compared to the Mela tumors may thus contribute to activation of the Smad pathway leading to an EMT-like gene expression signature. Accordingly, expression of hallmark EMT genes such as *Snai1/Snai1* and *Fn1* was downregulated in the presence of a JNK inhibitor in conditions that increased expression of the *Cdh1* gene in Amela tumor lines (Fig. 4).

In melanoma, both the Ras-Raf-MEK-ERK (MAPK) and the PI3K-AKT (AKT) signaling pathways are constitutively activated through multiple mechanisms, and thus exert several key functions in melanoma development and progression [52]. In human melanomas expressing the BRAF mutation V600E, up-regulation of Snai1 was found to be inversely correlated with progression-free and overall survival of patients [53]. Its up-regulation

appeared to depend mostly on ERK, but not on JNK activation in those melanomas. However, evidence for constitutive phospho-JNK expression was also found in human melanoma lines expressing BRAF or NRAS activating mutations [54]. In the Amela tumors, JNK appeared to induce smad-3 activity and to contribute, together with activated ERK to expression of Snai1 and repression of *Cdh1* gene expression. Constitutive production of the myeloid cell recruiting chemokine Ccl2 by the Amela cells also appeared dependent on both the JNK and the ERK activation pathways.

Of note, expression of another transcriptional regulator of the Snail-family, Slug a master regulator of neural crest cell specification and migration in many species [55,56] encoded by the *snai2* gene, was found to be down-modulated in the more aggressive Amela as compared to the Mela tumors (Fig. 1A – Tables S1). This observation is in line with data reporting higher expression of Slug in human benign melanocytic lesions prior to neoplastic transformation [55,57] than in primary or metastatic melanomas in a manner that correlated with the level of expression of transcription factor Mitf [57]. Indeed, down-regulation of the pigmentation program in Amela tumor cells was associated with down- and up-regulation of Mitf and Brn2 transcription factors, respectively. In a recent study visualizing

simultaneously increase of Brn2 promoter activity and decrease in pigmentation of melanoma cells, Brn2 expression was associated with a de-differentiated, invasive phenotype [58]. In a Braf mutant melanoma model in mice, increased Brn2 expression also led to increased invasiveness [59]. Among Brn2 target genes previously described in a melanoma line [60], some were up-regulated in Amela tumors and are known to play a role in invasiveness (*Hmga2*, *Twist1*, *Fn1*). Interestingly many potential Brn2 target genes significantly up-regulated in Amela tumors are involved in the development of the nervous system linking the melanomas to their neural crest cell origin (data not shown).

For the Amela tumors the observation that more rapidly growing amelanotic tumors develop in some cases at the site where pigmented melanomas initially developed [10,11] is in favor of a process of de-differentiation. *In vivo* transfer of primary melanotic tumors in immunodeficient mice also led to “outgrowth” of amelanotic tumors. Analysis at the clonal level should be performed to establish whether de-differentiation in pigmented cells gives rise to amelanotic cells or whether pre-existing amelanotic cells outgrew the pigmented cells. Since we generally observed only one tumor developing per mouse, the probability that two independent transformation events would be at the origin of the pigmented and amelanotic tumors at the same site is small. Therefore, a unique transformation event may have taken place in a precursor common to pigmented and non-pigmented cells of neuroectodermal origin, possibly at the level of a Schwann cell precursor [61]. Whether a non-pigmented cell constitutes the melanoma-initiating cell, as recently suggested [62], will require further studies. It is worth mentioning the potential importance of the notion that non-pigmented as well as pigmented cells may need to be targeted by therapeutic treatments. Indeed, immunotherapy protocols have often been directed at melanocyte differentiation antigens, which may not be expressed in non-pigmented tumor-precursor/-initiating/de-differentiated cells. In this respect the TiRP mouse melanoma model presents the advantage of being designed to express a known antigen concomitantly with the transforming oncogene. Ongoing pre-clinical immunotherapy protocols are testing the efficiency of treatments directed at such a model antigen [63].

Materials and Methods

Mice

Ethics statement. All procedures were approved by the Regional “Provence-Alpes-Cote d’Azur” Committee on Ethics for Animal Experimentation (authorization: #13.21, date: 11/02/2000) and were in accordance with French and European directives. All efforts were made to minimize animal suffering.

TiRP (*Tyr-iRas-PIA-transgenic Ink4a/Arf^{fllox/fllox}*) mice [10], kept on the B10.D2 background [11] were treated as described [10,11] for melanoma induction (Supplemental Information -SI- for details). Non-transgenic *Ink4a/Arf^{fllox/fllox}* mice, used as controls, never develop melanomas.

Mouse Melanoma Cell Lines

B16 mouse melanoma line B16F10 (ATCC number CRL-6475), originally derived by I. Fidler (M.D. Anderson Cancer Center, Houston, Tx), was received from Dr. AF Tilkin-Mariamé (INSERM-U563, Toulouse, France). Mela and Amela mouse melanoma cell lines were established in culture from, respectively, homogeneously melanotic and amelanotic induced melanomas in TiRP mice, as described [10] and were further cultured in DMEM (GibcoRL) with 10% FCS (see Text S1).

Microarrays Analysis

Gene expression profiles were analyzed by two-color microarrays on: (i) - induced Amela and Mela tumors (4 independent tumors of each type, being either homogeneously amelanotic (Amela) or homogeneously melanotic (Mela)) compared to each other or to control mice skin (pool from two control mice); (ii) - induced Amela tumors versus cultured lines established from induced Amela tumors (4 independent tumors). For each experimental sample, two technical replicates (dye-swaps) were examined.

Isolation of RNA from Melanoma Tumors and Tumor Cell Lines

Total RNA was isolated from melanoma frozen tissues or skin (conserved at -80°C in RNA later) using RNeasy Mini Kit column purification and digestion with RNase free DNaseI according to the manufacturer’s protocols (Qiagen). Total RNA from cultured melanoma lines was extracted using Trizol reagent (Invitrogen life technologies Inc.) and resuspended in RNase-free water. RNA quality and quantity were determined using a bioanalyzer (Agilent technologies) and a Nanodrop spectrophotometer ND-1000 (Nanodrop technology), respectively.

RNA Labeling and Hybridization

These steps were performed by the “Plate-Forme Transcriptome, Nice-Sophia Antipolis” as described [64] (see Text S1). Probe sequences are available on the MEDIANTE web site (<http://www.microarray.fr:8080/merge/index>).

Data Analysis

Fluorescence intensity measurements and data analyses were as described (see Text S1). Microarray data have been submitted to NCBI GEO database: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29304>.

Quantitative Reverse Transcriptase Chain-reaction

cDNA was generated using the superscript first-strand synthesis system for RT-PCR according to the manufacturer’s instruction (Invitrogen). Quantitative real time PCR was performed with a Prism 7500 fast real time PCR system using Sybr green PCR Master Mix (Applied Biosystem). Thermal cycle conditions and primers are detailed (see Text S1).

Active TGF β Measurement

The MFBF11 TGF-reporter cells expressing a plasmid containing SMAD-binding elements driving the expression of secreted alkaline phosphatase (SEAP), kindly provided by Ina Tesseur (Stanford University School of Medicine, Stanford, CA), were treated as described [27]. Amela cells and reporter cells (MFBF11) were incubated overnight in 1 ml serum-free DMEM. 500 μ l of the Amela cell supernatants were either acid-activated followed by neutralization to pH 7.4 or non-activated by addition of 100 μ l NaCl 0.5 M (see Text S1). Treated supernatants were added to reporter cells. SEAP activity was measured using Great Escape SEAP Reporter system 3 (BD Biosciences, San Jose, CA) with a Lmax plate photometer (Molecular Devices, Sunnyvale, CA). The same assay was performed using reporter cell lines expressing the green fluorescent protein (SBE-GFP) [28]. Expression of GFP was measured by flow cytometry (CANTO II-BD Biosciences) and data were analyzed using FlowJoTM software (Tree Star).

Cell Transduction with Lentiviral Reporter Constructs for Fluorescence Tracking of Smad3 Signaling

Amela and B16F10 cell lines were transduced with Lentiviral vectors encoding the reporter SBE-GFP [28] (see Text S1). Infected cells were selected on the basis of GFP expression in the presence of TGF β using a FACS.

Flow Cytometry

SBE-GFP-transduced melanoma cells, incubated overnight at 1×10^5 cells/well in 24-well flat-bottom tissue culture plates (BD Falcon, San Jose, CA), were washed twice with PBS and incubated in 1 ml serum-free DMEM/P/S for 24 h. After a further overnight incubation in the same medium or with TGF β 10 ng/ml (recombinant human TGF β ; R&D), GFP expression was analyzed by flow cytometry (CANTO II-BD Biosciences) and data were analyzed using FlowJoTM software (Tree Star).

Kinase Inhibitors

SBE-GFP-transduced melanoma cells were treated as above except for the addition of inhibitors during the overnight incubation in the presence or absence of TGF β 5 ng/ml. Inhibitors were Smad3 inhibitor SIS3 10 μ M (Calbiochem), TGF β RI kinase inhibitor SB431542 10 μ M, JNK inhibitor SP600125 10 μ M (Calbiochem) and ERK inhibitor PD 98059 (10 μ M). When testing the effect of kinase inhibitors on EMT or Ccl2 transcripts, Amela cells were plated at 10^5 cells in 1 ml FCS containing medium for 24 h, followed by 24 h in medium without FCS and 24 h in the same medium in the presence of control DMSO or inhibitors as above. For each tumor line, cells from 4 wells were pooled and processed for QRT-PCR analysis.

Immunofluorescence

Snap-frozen tumors in tissue-Tek (Sakura Finetek) were fixed in 4% paraformaldehyde, permeabilized with methanol and stained with a polyclonal rabbit anti-pSmad3L(Ser208/213) antibody (28029, IBL) or rabbit anti-pJNK antibody (ab4821, Abcam) and with anti-CD45 monoclonal antibody. Confocal microscopy was performed with a Zeiss LSM510 microscope. Image processing was performed with Zeiss LSM software and Adobe Photoshop.

Detection of Ccl2 Transcripts by QRT-PCR and Secreted Protein by ELISA

Amela cell lines were cultured as indicated above in the absence or presence of kinase inhibitors. Culture supernatants were collected and kept frozen for detection of secreted Ccl2 by ELISA. The cell pellets were treated for detection of Ccl2 transcripts by QRT-PCR, as described above. Mouse Ccl2 (MCP-1) ELISA ready-SET-Go! (eBioscience) was used for quantification of Ccl2 production by Amela tumor lines.

Statistical Analyses

Statistical analyses were performed with the Student's unpaired *t* test using GraphPad and two-tailed *P* values are given as follows: (*) *P* < 0.05; (**) *P* < 0.01; and (***) *P* < 0.001.

Supporting Information

Figure S1 Unsupervised Hierarchical Clustering of melanoma tumors and healthy skin samples. Each row represents a gene, and each column represents a sample. Each experimental sample is represented by 2 or 3 values associated to 2 or 3 different hybridizations. The expression level of each gene in a single tumor is relative to its median abundance across all tumors

and is depicted according to a color scale in which red and green expression levels are, respectively, above and below the median. The magnitude of deviation from the median is represented by the color saturation. The dendrogram of samples (matrix on top) represents overall similarities in gene expression profiles. Four clusters are shown: - clusters of genes highly expressed selectively in Amela (A) or in Mela (B) tumors; - clusters of genes which expression is up-regulated (C) or down-regulated (D) in both tumors as compared to healthy skin.

(PDF)

Figure S2 Heatmap output for the 80 most differentially expressed transcripts between Amela and Mela tumors.

Each row represents a gene and each column represents a sample. Each experimental sample is represented by 2 or 3 values associated to 2 or 3 different hybridizations. Expression values are represented as colors, where the range of colors (red, pink, light blue, dark blue) shows the range of expression values (high, moderate, low, lowest). These genes were provided in the GSEA plots shown in Fig. 2.

(PDF)

Figure S3 EMT signature gene expression in Amela tumors.

Snail expression in Amela (A–C) and Mela (D–F) tumors was analyzed by immunohistology on tumor sections. It shows Dapi staining for nuclei (white), anti-CD45 antibody staining for leukocytes (green) and anti-Snail antibody staining (red). Scale bars: 50- μ m (A, C, D, F) and 20- μ m (B, E). In C and F, the anti-Snail antibody was pre-incubated with the immunizing peptide (see Supplemental Methods). Data are representative of 3 tumors of each type.

(PDF)

Figure S4 Analysis of the TGF β 3 pathway in melanoma lines and tumors.

A. Supernatants from Amela^C and Amela^I cell lines incubated in serum-free DMEM were either acid treated (acid) or not (no treatment) and were tested for TGF β using a reporter line expressing SBE-GFP (see Methods). The mean of GFP fluorescence intensity is represented. Bars represent means $\pm$ s.e.m. of triplicate wells for 4 samples in one representative experiment. Serum-free DMEM (no TGF β) was used for baseline measurement. B. Control staining of Amela and Mela tumors analyzed by immunohistology in Fig. 4A in the presence of secondary goat anti-Rat fluorescent (Alexa546) antibody, but in the absence of Rat anti-Phospho-Smad3L antibody. Anti-CD45 mAb and Sytox blue staining are as in Fig. 4A.

(PDF)

Table S1 Genes involved in pigmentation, differentiation and development of melanocytes down-regulated or up-regulated in Amela versus Mela tumors as shown in Figure 1A.

(PDF)

Table S2 Genes characterizing immune response components or chemotaxis that show higher expression in Amela vs Mela tumors but are expressed at lower level in Amela lines in culture than in Amela tumors.

(PDF)

Table S3 Table representing the genes highly expressed in Amela tumors having one or multiple conserved Smad binding sites in their promoter (in silico analysis). For each gene, the conserved Smad binding sites (CAGA), their number and their *p* values are represented.

(PDF)

Acknowledgments

We thank Pascal Barbry and Kevin Lebrigand (CNRS, Sophia-Antipolis, Nice, France) for guidance on micro array analysis, Lee Leserman for suggestions on the manuscript and the CIML imaging and animal facilities personnel for assistance.

References

- Busca R, Ballotti R (2000) Cyclic AMP a key messenger in the regulation of skin pigmentation. *Pigment Cell Res* 13: 60–69.
- Herlyn M, Berking C, Li G, Satyamoorthy K (2000) Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. *Melanoma Res* 10: 303–312.
- Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. *Curr Opin Cell Biol* 17: 548–558.
- Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. *Nat Rev Mol Cell Biol* 7: 131–142.
- Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. *J Clin Invest* 119: 1420–1428.
- Radisky DC (2005) Epithelial-mesenchymal transition. *J Cell Sci* 118: 4325–4326.
- Peinado H, Quintanilla M, Cano A (2003) Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. *J Biol Chem* 278: 21113–21123.
- Gotzmann J, Huber H, Thallinger C, Wolschek M, Jansen B, et al. (2002) Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. *J Cell Sci* 115: 1189–1202.
- Janda E, Lehmann K, Killisch I, Jechlinger M, Hergert M, et al. (2002) Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. *J Cell Biol* 156: 299–313.
- Huijbers IJ, Krimpenfort P, Chomez P, van der Valk MA, Song JY, et al. (2006) An inducible mouse model of melanoma expressing a defined tumor antigen. *Cancer Res* 66: 3278–3286.
- Soudja SM, Wehbe M, Mas A, Chasson L, Powis de Tenboscche C, et al. (2010) Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. *Cancer Res* 70: 3515–3525.
- Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A* 98: 5116–5121.
- Cheli Y, Ohanna M, Ballotti R, Bertolotto C (2010) Fifteen-year quest for microphthalmia-associated transcription factor target genes. *Pigment Cell Melanoma Res* 23: 27–40.
- Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, et al. (2000) Microphthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. *Cancer Res* 60: 5012–5016.
- Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, et al. (2004) The Brn-2 transcription factor links activated BRAF to melanoma proliferation. *Mol Cell Biol* 24: 2923–2931.
- Goodall J, Carreira S, Denat L, Kobi D, Davidson I, et al. (2008) Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. *Cancer Res* 68: 7788–7794.
- Ryu B, Kim DS, Deluca AM, Alani RM (2007) Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. *PLoS One* 2: e594.
- Kamaraju AK, Bertolotto C, Chebath J, Revel M (2002) Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. *J Biol Chem* 277: 15132–15141.
- Du F, Nakamura Y, Tan TL, Lee P, Lee R, et al. (2010) Expression of snail in epidermal keratinocytes promotes cutaneous inflammation and hyperplasia conducive to tumor formation. *Cancer Res* 70: 10080–10089.
- Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. *Cancer Cell* 15: 195–206.
- Dominguez D, Montserrat-Sentis B, Virgos-Soler A, Guita S, Grueso J, et al. (2003) Phosphorylation regulates the subcellular location and activity of the snail transcriptional repressor. *Mol Cell Biol* 23: 5078–5089.
- Zhou BP, Deng J, Xia W, Xu J, Li YM, et al. (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. *Nat Cell Biol* 6: 931–940.
- Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, Ciszar K, Fong KS, et al. (2005) A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. *EMBO J* 24: 3446–3458.
- Zhang K, Rodriguez-Aznar E, Yabuta N, Owen RJ, Mingot JM, et al. (2012) Lats2 kinase potentiates Snail activity by promoting nuclear retention upon phosphorylation. *EMBO J* 31: 29–43.
- Massague J (2008) TGFbeta in Cancer. *Cell* 134: 215–230.
- Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. *Cell Res* 19: 156–172.
- Tesseur I, Zou K, Berber E, Zhang H, Wyss-Coray T (2006) Highly sensitive and specific bioassay for measuring bioactive TGF-beta. *BMC Cell Biol* 7: 15.

Author Contributions

Conceived and designed the experiments: MW AMSV SMS BVdE. Performed the experiments: MW AM LC SMS RG CPdV GV. Analyzed the data: MW AM LC RG GV AMSV. Wrote the paper: MW AMSV.

- Stuelten CH, Kamaraju AK, Wakefield LM, Roberts AB (2007) Lentiviral reporter constructs for fluorescence tracking of the temporospatial pattern of Smad3 signaling. *Biotechniques* 43: 289–290, 292, 294.
- Yamagata H, Matsuzaki K, Mori S, Yoshida K, Tahashi Y, et al. (2005) Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. *Cancer Res* 65: 157–165.
- Li D, Lin HH, McMahon M, Ma H, Ann DK (1997) Oncogenic raf-1 induces the expression of non-histone chromosomal architectural protein HMGI-C via a p44/p42 mitogen-activated protein kinase-dependent pathway in salivary epithelial cells. *The Journal of biological chemistry* 272: 25062–25070.
- Nielsen C, Thastrup J, Bottzauw T, Jaattela M, Kallunki T (2007) c-Jun NH2-terminal kinase 2 is required for Ras transformation independently of activator protein 1. *Cancer Res* 67: 178–185.
- Choi BY, Choi HS, Ko K, Cho YY, Zhu F, et al. (2005) The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity. *Nature structural & molecular biology* 12: 699–707.
- Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, et al. (2009) Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. *Clin Cancer Res* 15: 1931–1939.
- Ancrile B, Lim KH, Counter CM (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. *Genes Dev* 21: 1714–1719.
- Yang J, Splittergerber R, Yull FE, Kantrow S, Ayers GD, et al. (2010) Conditional ablation of Ikbk inhibits melanoma tumor development in mice. *J Clin Invest* 120: 2563–2574.
- Walter S, Bottazzi B, Govoni D, Colotta F, Mantovani A (1991) Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocyte chemoattractant protein/JE. *International journal of cancer Journal international du cancer* 49: 431–435.
- Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, et al. (2007) Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. *The Journal of investigative dermatology* 127: 2031–2041.
- Huang B, Lei Z, Zhao J, Gong W, Liu J, et al. (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. *Cancer Lett* 252: 86–92.
- Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, et al. (2011) COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. *Cancer Res* 71: 2664–2674.
- Zaidi MR, De Fabo EC, Noonan FP, Merlino G (2012) Shedding light on melanocyte pathobiology in vivo. *Cancer Res* 72: 1591–1595.
- Zaidi MR, Davis S, Noonan FP, Graff-Cherry C, Hawley TS, et al. (2011) Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. *Nature* 469: 548–553.
- Grotegut S, von Schweinitz D, Christofori G, Lembre F (2006) Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. *EMBO J* 25: 3534–3545.
- Poser I, Dominguez D, de Herrerias AG, Varnai A, Buettner R, et al. (2001) Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. *J Biol Chem* 276: 24661–24666.
- Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR (2008) Cadherin switching. *J Cell Sci* 121: 727–735.
- Li G, Satyamoorthy K, Herlyn M (2001) N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. *Cancer Res* 61: 3819–3825.
- Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat Cell Biol* 2: 76–83.
- Kuphal S, Palm HG, Poser I, Bosserhoff AK (2005) Snail-regulated genes in malignant melanoma. *Melanoma Res* 15: 305–313.
- Nieto MA (2002) The snail superfamily of zinc-finger transcription factors. *Nat Rev Mol Cell Biol* 3: 155–166.
- Moustakas A, Heldin CH (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. *Cancer Sci* 98: 1512–1520.
- Sekimoto G, Matsuzaki K, Yoshida K, Mori S, Murata M, et al. (2007) Reversible Smad-dependent signaling between tumor suppression and oncogenesis. *Cancer Res* 67: 5090–5096.
- Matsuzaki K, Kitano C, Murata M, Sekimoto G, Yoshida K, et al. (2009) Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer. *Cancer Res* 69: 5321–5330.
- Meier F, Schitteck B, Busch S, Garbe C, Smalley K, et al. (2005) The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular

- targets for the effective treatment of advanced melanoma. *Front Biosci* 10: 2986–3001.
53. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, et al. (2009) Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. *J Exp Med* 206: 221–232.
 54. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, et al. (2007) Rewired ERK-JNK signaling pathways in melanoma. *Cancer Cell* 11: 447–460.
 55. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, et al. (2005) The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. *Nature genetics* 37: 1047–1054.
 56. LaBonne C, Bronner-Fraser M (2000) Snail-related transcriptional repressors are required in *Xenopus* for both the induction of the neural crest and its subsequent migration. *Developmental biology* 221: 195–205.
 57. Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA, et al. (2012) Slug expression during melanoma progression. *The American journal of pathology* 180: 2479–2489.
 58. Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, et al. (2009) Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. *Cancer Res* 69: 7969–7977.
 59. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, et al. (2011) Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. *Cancer Cell* 19: 45–57.
 60. Kobi D, Steunou AL, Dembele D, Legras S, Larue L, et al. (2010) Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene. *Pigment Cell Melanoma Res* 23: 404–418.
 61. Adameyko I, Lallemand F, Aquino JB, Pereira JA, Topilko P, et al. (2009) Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. *Cell* 139: 366–379.
 62. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, et al. (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. *Nature* 466: 133–137.
 63. Grange M, Buferne M, Verdeil G, Leserman L, Schmitt-Verhulst AM, et al. (2012) Activated STAT5 promotes long-lived cytotoxic CD8⁺ T cells that induce regression of autochthonous melanoma. *Cancer Res* 72: 76–87.
 64. Le Brigand K, Russell R, Moreilhon C, Rouillard JM, Jost B, et al. (2006) An open-access long oligonucleotide microarray resource for analysis of the human and mouse transcriptomes. *Nucleic Acids Res* 34: e87.

Supplemental information

Supplemental methods

Mice

TiRP-10B;Ink4a/Arf flox/flox mice (Huijbers et al 2006) backcrossed to the B10.D2 strain (B10.D2/nOlaHsd, H-2d) Harlan (Gannat, France)) for more than 10 generations and hereafter called TiRP mice were previously described (Soudja et al 2010). TiRP mice devoid of adaptive immune components were established after crossing with Rag-1 KO B10.D2 (RagKO) mice (Soudja et al 2010), and are hereafter called TiRP RagKO mice. Treatment of TiRP mice with 4OH-tamoxifen (Sigma) was as previously described (Huijbers et al 2006). Mice were housed under specific pathogen-free conditions.

Melanoma cell lines

Established in culture from Amela melanomas developing in TiRP and TiRP RagKO mice as described (Huijbers et al 2006), melanoma cell lines were further cultured in DMEM complete medium (GibcoRL), supplemented with 10% FCS, enriched with glutamine, penicillin-streptomycin, HEPES and Sodium pyruvate.

RNA labeling and hybridization

These steps were performed by the “Plate-Forme Transcriptome, Nice-Sophia Antipolis” under direction of Dr. Pascal Barbry (CNRS-UMR6097, Nice-Sophia-Antipolis, France) as described (Le Brigand et al 2006). Briefly, 1 μ g total RNA was amplified and labeled with Cy3 and Cy5 fluorochromes using the Amino Allyl MessageAmp aRNA kit according to the manufacturer’s (Ambion) protocol. Cy3-and Cy5-labeled cRNAs were fragmented using Fragmentation Buffer (Agilent), dissolved in Hybridization Buffer (Agilent) and hybridized to pan-genomic mouse micro arrays of the RNG/MRC resource (<http://www.microarray.fr>). These micro arrays harbor 24109 50mer oligonucleotides (Le Brigand et al 2006).

Data analysis

Fluorescence intensity measurements were subjected to automatic background subtraction. The Cy3/Cy5 ratios were normalized to the value of the median ratio of all spots in the array and bad spots were excluded from the analysis, as described (Le Brigand et al 2006). All ratio values were log-transformed (base 2), and duplicated spots in the array were averaged. A single value for each gene was obtained. For our purposes, expression of a gene was deemed to be up regulated or down regulated if there was at least a 2-fold difference in the expression and if the P value was <0.001. The regulated genes were functionally classified manually on the basis of exhaustive searches in Pubmed and gene ontology. The open source R software

package (<http://www.r-project.org>) and tools from the Bioconductor project (<http://www.bioconductor.org>) Gene Cluster, TreeView, and Excel were used for processing and analysis of the micro array data. Data from each hybridization were maintained in a database for analysis.

Quantitative reverse transcriptase chain-reaction

cDNA was generated using the superscript first-strand synthesis system for RT-PCR according to the manufacturer's instruction (Invitrogen). Quantitative real time PCR was performed with a Prism 7500 fast real time PCR system using Sybr green PCR Master Mix (Applied Biosystem). The thermal cycle conditions were as follows: hold for 10 min at 95° C followed by two steps PCR for 40 cycles at 95°C for 15 s and at 60°C for 1 min. Optimal annealing temperature was predetermined to ensure single amplified product. All samples were performed in duplicate. The β -actin gene was used as control. Threshold cycle (Ct) was assigned to various products according to the cycle number at which fixed, low fluorescence intensity was achieved. $\Delta Ct = Ct(\text{target}) - Ct(\text{actin})$, the difference between the Ct value of the target gene and the Ct value of the reference gene (actin). The fold increase of the target gene mRNA was calculated according to the expression $2^{-\Delta\Delta Ct}$, where $2^{-\Delta\Delta Ct}$ is the difference between ΔC (experimental sample) and ΔC (control sample).

Primers:

Gene		Primer sequence 5'---3'	Product size (bp)
β -Actin	F ^a :	GACGGCCAGGTCATCACTATTG	72
	B ^b :	CAAGAAGGAAGGCTGGAAAAGA	
E-Cadherin	F:	GTCAGATCTCCCTGAGTTCG	392
	B:	GCACCCACACACATACTC	
Brn2	F:	CGGCGGTTTGCTCTATTC	118
	B:	ATGGTGTGGCTCATCGTG	
Hmga2	F:	AGCAAAAACAAGAGCCCCCTCTA	94
	B:	ACGACTTGTTGTGGCCATTTC	
Id2	F:	AAAACAGCCTGTCGGACCAC	121
	B:	CTGGGCACCAGTTCCTTGAG	
Snail	F:	ACCCCCGCCGGAAGCCCAACT	128
	B:	AGCGGCGGGGTTGAGGACCTC	
Twist	F:	CGGGTCATGGCTAACGTG	243
	B:	CAGCTTGCCATCTTGGAGTC	

Mitf

F: GCCTTGTTTATGGTGCCTTC

73

B: GTCCTCCTCCCTCTACTTTCTGT

a: F:forward b: B:Backward

Active TGF β measurement

The MFBF11 TGF-reporter cells expressing a plasmid containing SMAD-binding elements driving the expression of secreted alkaline phosphatase (SEAP), kindly provided by Ina Tesseur (Stanford University School of Medicine, Stanford, CA), were treated as described (Tesseur et al. 2006). Amela cells and reporter cells (MFBF11) were seeded at 1×10^5 cells/well in 24-well flat-bottom tissue culture plates (BD Falcon, San Jose, CA). After overnight incubation, cells were washed twice with PBS and incubated in 1 ml serum-free DMEM supplemented with Penicillin/streptomycin (DMEM/P/S). 500 μ l of these Amela cells supernatant were either acid-activated by adding 50 μ l 1M HCl at room temperature for 10min followed by neutralization to pH 7.4 with 1M NaOH or non-activated by addition of 100 μ l NaCl 0.5M. Treated supernatants were added to reporter cells. SEAP activity was measured using Great EscAPe SEAP Reporter system 3 (BD Biosciences, San Jose, CA) with a Lmax plate photometer (Molecular Devices, Sunnyvale, CA). The same assay was performed using reporter cell lines expressing the green fluorescent protein (SBE-GFP) (Stuelten et al. 2007). Expression of GFP was measured by flow cytometry (CANTO II-BD Biosciences) and data were analyzed using FlowJoTM software (Tree Star).

Cell transduction with lentiviral reporter constructs for fluorescence tracking of Smad3 signaling

Amela and B16 cell lines were transduced with Lentiviral vectors encoding the reporter SBE-GFP (Stuelten et al 2007), kindly provided by Dr. Christina Stuelten (NCI, NIH, Bethesda, MD). Cells were seeded at 1×10^4 cells/well in 96-well flat-bottom tissue culture plates, lentiviral particles were added to the cells in the presence of polybrene (0.8mg/ml). Infected cells were selected on the basis of GFP expression in the presence of TGF β using a FACS.

Supplemental legend to Table 3.

References corresponding to Table 3:

1. Untergasser, G., et al., *Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation*. Mech Ageing Dev, 2005. **126**(1): p. 59-69.
2. Kapoun, A.M., et al., *Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression*. Mol Pharmacol, 2006. **70**(2): p. 518-31.
3. Venkatesan, N., P.J. Roughley, and M.S. Ludwig, *Proteoglycan expression in bleomycin lung fibroblasts: role of transforming growth factor-beta(1) and interferon-gamma*. Am J Physiol Lung Cell Mol Physiol, 2002. **283**(4): p. L806-14.
4. Verrecchia, F., M.L. Chu, and A. Mauviel, *Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach*. J Biol Chem, 2001. **276**(20): p. 17058-62.
5. Gaspar, N.J., et al., *Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness*. Mol Pharmacol, 2007. **72**(1): p. 152-61.
6. Valcourt, U., et al., *TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition*. Mol Biol Cell, 2005. **16**(4): p. 1987-2002.
7. Xie, L., et al., *Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line*. Breast Cancer Res, 2003. **5**(6): p. R187-98.
8. Saharinen, J., et al., *Latent transforming growth factor-beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-beta action*. Cytokine Growth Factor Rev, 1999. **10**(2): p. 99-117.
9. Dong, Y.W., X.P. Wang, and K. Wu, *Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition*. World J Gastroenterol, 2009. **15**(4): p. 441-8.
10. Ortiz, C.O., et al., *Transforming growth factor-beta regulation of the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts*. J Bone Miner Res, 2003. **18**(6): p. 1066-72.
11. Douthwaite, J.A., et al., *Effects of transforming growth factor-beta1 on renal extracellular matrix components and their regulating proteins*. J Am Soc Nephrol, 1999. **10**(10): p. 2109-19.
12. Zavadil, J., et al., *Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta*. Proc Natl Acad Sci U S A, 2001. **98**(12): p. 6686-91.
13. Levy, L. and C.S. Hill, *Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses*. Mol Cell Biol, 2005. **25**(18): p. 8108-25.
14. Kowanzetz, M., et al., *Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein*. Mol Cell Biol, 2004. **24**(10): p. 4241-54.
15. Cabello-Verrugio, C. and E. Brandan, *A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1*. J Biol Chem, 2007. **282**(26): p. 18842-50.

16. Hu, K., et al., *Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling*. J Clin Invest, 2007. **117**(12): p. 3821-32.
17. Ge, G. and D.S. Greenspan, *BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein*. J Cell Biol, 2006. **175**(1): p. 111-20.
18. Salazar, K.D., S.M. Lankford, and A.R. Brody, *Mesenchymal stem cells produce Wnt isoforms and TGF-beta1 that mediate proliferation and procollagen expression by lung fibroblasts*. Am J Physiol Lung Cell Mol Physiol, 2009. **297**(5): p. L1002-11.
19. Massague, J., *TGFbeta in Cancer*. Cell, 2008. **134**(2): p. 215-30.
20. Dzwonek, J., et al., *Smad3 is a key nonredundant mediator of transforming growth factor beta signaling in Nme mouse mammary epithelial cells*. Mol Cancer Res, 2009. **7**(8): p. 1342-53.
21. Abboud, S.L., *Regulation of platelet-derived growth factor A and B chain gene expression in bone marrow stromal cells*. J Cell Physiol, 1995. **164**(2): p. 434-40.
22. Berking, C., et al., *Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling*. Cancer Res, 2001. **61**(22): p. 8306-16.
23. Katabami, K., et al., *Transforming growth factor-beta1 upregulates transcription of alpha3 integrin gene in hepatocellular carcinoma cells via Ets-transcription factor-binding motif in the promoter region*. Clin Exp Metastasis, 2005. **22**(7): p. 539-48.
24. Kuo, Y.C., et al., *Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase*. Int J Cancer, 2009. **124**(11): p. 2568-76.

Supplemental figure legends.

Figure S1. Unsupervised Hierarchical Clustering of melanoma tumors and healthy skin samples.

Each row represents a gene, and each column represents a sample. Each experimental sample is represented by 2 or 3 values associated to 2 or 3 different hybridizations. The expression level of each gene in a single tumor is relative to its median abundance across all tumors and is depicted according to a color scale in which red and green expression levels are, respectively, above and below the median. The magnitude of deviation from the median is represented by the color saturation. The dendrogram of samples (matrix on top) represents overall similarities in gene expression profiles. Four clusters are shown: - clusters of genes highly expressed selectively in Amela (A) or in Mela (B) tumors; - clusters of genes which expression is up-regulated (C) or down-regulated (D) in both tumors as compared to healthy skin.

Figure S2. Heatmap output for the 80 most differentially expressed transcripts between Amela and Mela tumors.

Each row represents a gene and each column represents a sample. Each experimental sample is represented by 2 or 3 values associated to 2 or 3 different hybridizations. Expression values are represented as colors, where the range of colors (red, pink, light blue, dark blue) shows the range of expression values (high, moderate, low, lowest). These genes were provided in the GSEA plots shown in Fig.2.

Figure S3. EMT signature gene expression in Amela tumors.

Snail expression in Amela and Mela tumors was analyzed by immunohistology on ~~ex-vivo~~ tumors sections. It shows Topro-3 blue staining for nuclei (Blue) and anti-Snail antibody staining (red) together with anti-CD45 antibody staining for leukocytes (green). Scale bars: 10- μ m.

Figure S4. Analysis of the TGF β 3 pathway in melanoma lines and tumors.

A. Supernatants from Amela^C and Amela^I cell lines incubated in serum-free DMEM were either acid treated (acid) or not (no treatment) and were tested for TGF β using a reporter line expressing SBE-GFP (see Methods). The mean of GFP fluorescence intensity is represented. Bars represent means $\pm$ s.e.m. of triplicate wells in one representative experiment. Serum-free DMEM (no TGF- β) was used for baseline measurement. B. Control staining of Amela and Mela tumors analyzed by immunohistology in Fig.4A in the presence of secondary goat anti-Rat fluorescent (Alexa546) antibody, but in the absence of Rat anti-Phospho-Smad3L antibody. Anti-CD45 mAb and Sytox blue staining are as in Fig.4A.

Table S1. Genes involved in pigmentation, differentiation and development of melanocytes down-regulated or up-regulated in Amela versus Mela tumors as shown in Figure 1A.

Table S2. Genes characterizing immune response components or chemotaxis that show higher expression in Amela vs Mela tumors but are expressed at lower level in Amela lines in culture than in Amela tumors.

Table S3. Table representing the genes highly expressed in Amela tumors having one or multiple conserved Smad binding sites in their promoter (in silico analysis). For each gene, the conserved Smad binding sites (CAGA), their number and their p values are represented.

Table S1. Genes involved in pigmentation, differentiation and development of melanocytes differentially expressed by Mela versus Amela tumors.

Gene Symbol	Gene name	^(b) Log2 ratio Amela/Mela
^(a) Up-regulated in Mela		
Dct	Dopachrome tautomerase	-5.985
Sox9	SRY-box containing gene 9	-5.646
Tyrp1	Tyrosinase related protein 1	-5.392
Si	Silver	-5.373
Mlana	Melan-A	-5.262
Slc45a2	Solute carrier family 45, member 2	-4.564
S100b	S100 calcium binding protein B	-3.506
Mc1r	Melanocortin 1 receptor	-3.027
Mcoln3	Mucolipin 3	-2.976
Mitf	Microphthalmia transcription factor	-2.310
Sox10	SRY-box containing gene 10	-2.095
Pax3	Paired box gene 3	-2.045
Kit	Kit oncogene	-1.808
Mlph	Melanophilin	-1.412
Psen2	Presenilin 2	-1.408
Snai2	Snail homolog 2 (drosophila)	-0.897*
ErbB2	V-erb-b2 erythroblastic leukemia viral oncogene homolog 2	-0.755*
^(c) Up-regulated in Amela		
Pou3f2	POU domain, class 3, transcription factor 2	1.31

(a) Genes involved in pigmentation, differentiation and development of melanocytes that show higher expression in Mela versus Amela ex vivo tumors

(b) Ratio of gene expression as log2 Amela/Mela < -1 with p values < 0.05;

* Ratio of gene expression as log2 Amela/Mela between -1 and 0 with p values < 0.05

(c) Ratio of gene expression as log2 Amela/Mela > 1 with p value < 0.05.

Table S2. Amela tumor-expressed genes characterizing tumor-infiltrating leukocytes.

Gene symbol	Gene name	^(b) Log2 ratio Amela/Line	^(c) Log2 ratio Amela/Mela
^(a) <i>Immune response and chemotaxis</i>			
Emr1	EGF-like module containing, mucin-like, hormone receptor-like sequence 1	5.94	0.13
Ly86	Lymphocyte antigen 86	5.72	1.09
Mrc1	Mannose receptor, c type 1	5.60	1.12
Fcgr3	Fc gamma receptor 3	4.86	0.84*
Fbn1	Fibrilin 1	4.77	1.16
Msr2	Fc receptor-like S, scavenger receptor	4.60	1.12
Ccl12	Chemokine (C-C motif) ligand 12	4.19	1.71
Mmp3	Matrix metalloproteinase 3	4.18	2.05
Cd72	CD72 antigen	4.10	1.85
C1qa	Complement component 1, q subcomponent, A chain	4.08	1.39
Cx3cr1	Chemokine (C-X3-C) receptor 1	3.90	1.51
Mmp23	Matrix metalloproteinase 23	3.62	1.27
C1qr1	CD93 antigen	3.35	1.81
Csf1r	Colony stimulating factor 1 receptor	2.93	1.10
Slamf9	SLAM family member 9	2.86	1.05
Ltbp2	Latent transforming growth factor beta binding protein 2	2.78	1.16
Ccr1	Chemokine (C-C motif) receptor 1	2.61	2.07
Tgfb2	Transforming growth factor, beta receptor II	2.24	0.96*
Lsp1	Lymphocyte specific 1	2.19	1.28
Tlr1	Toll like receptor 1	2.18	1.18
Cfh	Complement component factor h	2.01	2.15
Ltbp3	Latent transforming growth factor beta binding protein 3	1.57	0.96*
Mmp2	Matrix metalloproteinase 2	1.34	0.91*


(a) Genes characterizing immune response components or chemotaxis that show higher expression in Amela versus Mela ex vivo tumors but are expressed at lower level in Amela lines in culture than in Amela ex vivo tumors.

(b) Ratio of gene expression as Log2 Amela/Cultured Amela line > 1 with p value < 0.001;


(c) Ratio of gene expression as Log2 Amela/Mela > 1 with p value < 0.001;

* Ratio of gene expression as log2 Amela/Mela between 0 and 1 with p values < 0.05.


A



B



C



D




Figure S1




Figure S2




Figure S3



A**B**

Figure S4